TRACP-5b test to help diagnose and monitor giant cell tumor of bone

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective observational study will measure TRACP-5b levels in blood from adults with newly diagnosed or previously treated giant cell tumor of bone and compare results to clinical findings, imaging, and available histology. The goal is to see if TRACP-5b reflects disease activity or recurrence risk and could support noninvasive monitoring during routine care. Participants will have regular blood draws during outpatient visits as part of standard follow-up. No experimental therapy is given; the study observes and correlates biomarker data with disease status. Findings may inform future use of TRACP-5b in surveillance strategies for GCTB.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed Giant Cell Tumor of Bone
* Newly diagnosed patients or patients undergoing long-term follow-up after previous treatment
* Age ≥18 years
* Ability to understand the study procedures and provide written informed consent

Exclusion Criteria:

* Concurrent diseases significantly affecting bone metabolism, including metabolic bone disorders
* Inability or unwillingness to provide informed consent
* Patients unable to comply with routine follow-up procedures
* Active conditions that may substantially influence serum TRACP-5b levels independently of Giant Cell Tumor of Bone evaluation

Where it's running

• First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
  Brno, Czechia Recruiting

Study contacts

• Principal investigator: Vasileios Apostolopoulos, M.D., Ph.D. — First Department of Orthopedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
• Study coordinator: Vasileios Apostolopoulos, M.D., Ph.D.
• Email: vasileios.apostolopoulos@fnusa.cz
• Phone: +420722101065

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Indocyanine green fluorescence to find leftover giant cell tumor tissue during surgery

  We will try a dye called indocyanine green with near-infrared imaging during surgery to help surgeons spot any remaining giant cell tumor tissue in people having surgery for GCTB.

  Recruiting Phase 4 Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai · NCT07315828

• PROMIS questionnaires and smartphone mobility tracking after sarcoma surgery

  This project tests whether PROMIS questionnaires together with a new smartphone app can track recovery and mobility in adults undergoing surgery for sarcoma or giant cell tumor of bone.

  Recruiting at 2 sites University of Calgary · Phoenix, Arizona and 3 other locations · NCT07227961

• Using ICG imaging to improve surgery for giant cell tumors of bone

  This study is testing if a special imaging technique can help surgeons find and remove all parts of giant cell tumors in the bone to reduce the chances of them coming back after surgery.

  Recruiting Phase 1/2 Peking University People's Hospital · Beijing, Beijing Municipality · NCT06647901

• Using zoledronic acid-loaded bone cement to reduce recurrence of giant cell bone tumors after surgery

  This study tests if using a special bone cement with a drug can help prevent giant cell bone tumors from coming back after surgery, compared to regular bone cement.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT05595603

• Using bisphosphonate to reduce tumor recurrence in bone tumors

  This study is testing if using a special bone cement with bisphosphonate during surgery can help prevent giant cell tumors in bones from coming back and improve recovery compared to regular surgery alone.

  Recruiting at 12 sites Phase 3 St. Louis University · Los Angeles, California and 15 other locations · NCT03295981

• Pimicotinib for Japanese people with tenosynovial giant cell tumor (J-MANEUVER)

  This trial will test whether pimicotinib is safe, reaches effective blood levels, and improves symptoms in Japanese participants with unresectable tenosynovial giant cell tumor.

  Recruiting at 4 sites Phase 2 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Chūōku and 3 other locations · NCT07499362

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.